In the field of nanomedicine, CEA - Léti has developed, over the past 9 years, a growing expertise in molecular optical imaging based on fluorescence imaging, and
on nanocarriers for drug delivery.
Not exact matches
A common assumption is that once a
nanocarrier is created, it maintains its size and shape
on the shelf as well as in the body.
«With further research we hope to create a nontoxic
nanocarrier that could provide targeted delivery of the TM - 025 and TM - 026 analogs specifically to cancer cells,» said Gitali Indra, an OSU assistant professor and also a lead and corresponding author
on the study.
However, the reality is that
nanocarriers may not always reach their intended target in sufficient numbers because of a constraint
on their ability to transit through the blood vessel wall at the tumor site, leading the encapsulated drugs to be diverted or lost before they can deliver their payload.